UCB (ENXTBR:UCB) - Cours de l'action, nouvelles et analyse

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

UCB Aperçu des actions

UCB SA, société biopharmaceutique, développe des produits et des solutions pour les personnes atteintes de maladies neurologiques et immunologiques dans le monde entier.

A propos de l'entreprise

UCB analyse fondamentale
Score flocon de neige
Évaluation	2/6
Croissance future	4/6
Performances passées	1/6
Santé financière	4/6
Dividendes	0/6

Récompenses

Se négocie à 57.2% en dessous de notre estimation de sa juste valeur

Les bénéfices devraient augmenter 35.5% par an

Analyse des risques

Les marges bénéficiaires (4.4%) sont inférieures à celles de l'année dernière (6.5%)

UCB SA Concurrents

Financière de Tubize

ENXTBR:TUB

€5.4b

Jiangsu Hengrui Medicine

SHSE:600276

CN¥280.6b

Otsuka Holdings

TSE:4578

JP¥4.6t

Takeda Pharmaceutical

TSE:4502

JP¥6.9t

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour UCB
Historique des cours de bourse
Prix actuel de l'action	€163.70
Plus haut sur 52 semaines	€165.75
Plus bas sur 52 semaines	€65.40
Bêta	0.36
1Variation sur 1 mois	6.82%
Variation sur 3 mois	28.19%
Variation sur 1 an	97.09%
3Variation sur 3 ans	66.97%
Variation sur 5 ans	140.10%
Évolution depuis l'introduction en bourse	53,548.21%

Nouvelles et mises à jour récentes

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Jul 28

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Jul 15

Recent updates

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

Jul 28

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Jul 15

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Apr 19

UCB SA Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jul 31

Is UCB (EBR:UCB) A Risky Investment?

Jun 21

UCB SA's (EBR:UCB) Intrinsic Value Is Potentially 96% Above Its Share Price

May 13

Is UCB (EBR:UCB) Using Too Much Debt?

Mar 18

Will Weakness in UCB SA's (EBR:UCB) Stock Prove Temporary Given Strong Fundamentals?

Feb 28

Rendement pour les actionnaires

	UCB	BE Pharmaceuticals	BE Marché
7D	1.7%	2.0%	0.7%
1Y	97.1%	21.2%	6.0%

Rendement vs Industrie: UCB a dépassé le secteur Belgian Pharmaceuticals qui a rapporté 20 % au cours de l'année écoulée.

Rendement vs marché: UCB a dépassé le marché Belgian qui a rapporté 5 % au cours de l'année écoulée.

Volatilité des prix

Is UCB's price volatile compared to industry and market?
UCB volatility
UCB Average Weekly Movement	3.3%
Pharmaceuticals Industry Average Movement	5.2%
Market Average Movement	3.5%
10% most volatile stocks in BE Market	7.3%
10% least volatile stocks in BE Market	2.4%

Cours de l'action stable: UCB n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: La volatilité hebdomadaire de UCB ( 3% ) est restée stable au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1925	9,000	Jean-Christophe Tellier	www.ucb.com

UCB SA, une société biopharmaceutique, développe des produits et des solutions pour les personnes souffrant de maladies neurologiques et immunologiques dans le monde entier. Les principaux produits de la société comprennent Cimzia pour les maladies inflammatoires médiées par le TNF, ainsi que la spondylarthrite ankylosante, la spondyloarthrite axiale, la maladie de Crohn, la spondyloarthrite axiale non radiographique, le psoriasis en plaques, l'arthrite psoriasique et la polyarthrite rhumatoïde ; Vimpat, Keppra et Briviact pour l'épilepsie ; Neupro pour la maladie de Parkinson et le syndrome des jambes sans repos ; Nayzilam, un traitement de secours par pulvérisation nasale pour les crises d'épilepsie ; et Zyrtec et Xyzal pour les allergies. Elle propose également Evenity pour le traitement de l'ostéoporose chez les femmes ménopausées, Bimzelx pour le traitement du psoriasis en plaques, de l'arthrite psoriasique et de la spondylarthrite axiale, et Fintepla pour le traitement du syndrome de Dravet.

UCB SA Résumé des fondamentaux

Comment les bénéfices et les revenus de UCB se comparent-ils à sa capitalisation boursière ?
UCB statistiques fondamentales
Capitalisation boursière	€31.06b
Bénéfices(TTM)	€240.00m
Recettes(TTM)	€5.45b

129.4x

Ratio P/E

5.7x

Ratio P/S

Le site UCB est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
UCB compte de résultat (TTM)
Recettes	€5.45b
Coût des recettes	€1.76b
Marge brute	€3.70b
Autres dépenses	€3.46b
Les revenus	€240.00m

Derniers bénéfices déclarés

Jun 30, 2024

Prochaine date de publication des résultats

Feb 27, 2025

Résultat par action (EPS)	1.27
Marge brute	67.80%
Marge bénéficiaire nette	4.40%
Ratio dettes/capitaux propres	31.8%

Quelles ont été les performances à long terme de UCB?

Voir les performances historiques et les comparaisons

Dividendes

0.8%

Rendement actuel des dividendes

108%

Ratio de distribution

UCB Aperçu des actions

Récompenses

Analyse des risques

UCB SA Concurrents

ENXTBR:TUB

€5.4b

SHSE:600276

CN¥280.6b

TSE:4578

JP¥4.6t

TSE:4502

JP¥6.9t

Historique des prix et performances

Nouvelles et mises à jour récentes

Consensus EPS estimates increase by 14%

Price target increased by 8.5% to €153

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Price target increased by 7.2% to €135

Recent updates

Consensus EPS estimates increase by 14%

Price target increased by 8.5% to €153

Analysts Have Made A Financial Statement On UCB SA's (EBR:UCB) Half-Yearly Report

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

Investors Still Waiting For A Pull Back In UCB SA (EBR:UCB)

Price target increased by 7.2% to €135

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

Dividend of €0.95 announced

Shareholders Will Probably Not Have Any Issues With UCB SA's (EBR:UCB) CEO Compensation

Consensus EPS estimates increase by 18%

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

Is UCB (EBR:UCB) A Risky Investment?

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Price target increased by 9.4% to €111

Consensus EPS estimates fall by 14%

Earnings Tell The Story For UCB SA (EBR:UCB) As Its Stock Soars 26%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB SA's (EBR:UCB) P/E Is On The Mark

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB (EBR:UCB) Takes On Some Risk With Its Use Of Debt

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

Is UCB (EBR:UCB) Using Too Much Debt?

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Are Investors Undervaluing UCB SA (EBR:UCB) By 48%?

Upcoming dividend of €0.93 per share at 1.5% yield

UCB's (EBR:UCB) Upcoming Dividend Will Be Larger Than Last Year's

Does UCB (EBR:UCB) Have A Healthy Balance Sheet?

Consensus EPS estimates fall by 17%

Consensus EPS estimates fall by 16%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Here's Why UCB (EBR:UCB) Can Manage Its Debt Responsibly

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

These 4 Measures Indicate That UCB (EBR:UCB) Is Using Debt Reasonably Well

First half 2022 earnings released

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated

Consensus forecasts updated